EdiGene Raises $67 Million for Clinical Trials of Gene Edited Drugs
October 13, 2020 at 06:30 AM EDT
China 's EdiGene raised $67 million in a Series B round to develop its genome editing technologies. The company is developing a portfolio of molecules aimed at genetic diseases and cancer, and it also offers drug discovery services using its CRISPR/Cas 9 proprietary high-throughput screening platforms. Founded in 2015, EdiGene is headquartered in Beijing , with operations in Guangzhou and Boston . The company said it would use the proceeds to advance its drug candidates into clinical trials. More details.... Share this with colleagues: // //
